Personalized support begins with MyAlcon Together
The MyAlcon Together Patient Support program has been designed to help meet each patient's unique needs and help them get the most out of treatment with ROCKLATAN®
Customizable program offerings include:
Personalized nurse support that can help educate patients about their ROCKLATAN® prescription
Nurses provide personalized telephone support and education in over 200 languages to answer general questions about glaucoma and their IOP-lowering treatment
Patients can save on prescriptions with the Alcon Savings Card
Eligible, commercially insured patients may pay as little as $30 with the Savings Card*
Tips, reminders, and resources that may help keep their ROCKLATAN® treatment on track
Patients can receive text and email messages with tips for instilling drops, prescription refills, and other useful resources to help them stay on top of their prescription
Encourage your patients to enroll in the MyAlcon Together Patient Support program
*Restrictions apply. Patients with federal or state prescription coverage, such as Medicare or Medicaid, are not eligible for the Savings Card. See AlconRxSavings.com for full terms & conditions.
Alcon is committed to supporting patient access to medications
IOP=Intraocular pressure.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
- Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.
- Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.
- Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.
- Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.
- Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.
- Remove contact lenses prior to administration and reinsert 15 minutes after administration.
INDICATIONS AND USAGE
ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Adverse Reactions
The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Please click here for full prescribing information for ROCKLATAN® Solution.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.